The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ

Michaela Semeraro, Julien Adam, Gautier Stoll, Emilie Louvet, Kariman Chaba, Vichnou Poirier-Colame, Allan Sauvat, Laura Senovilla, Erika Vacchelli, Norma Bloy, Juliette Humeau, Aitziber Buque, Oliver Kepp, Laurence Zitvogel, Fabrice André, Marie Christine Mathieu, Suzette Delaloge, Guido Kroemer

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    52 Citations (Scopus)

    Résumé

    In a series of 248 tumor samples obtained from image-guided biopsies from patients diagnosed with ductal carcinoma in situ of the breast, we attempted to identify biomarkers that predict microinfiltration at definitive surgery or relapse during follow-up. For this, we used immunohistochemical methods, followed by automated image analyses, to measure the mean diameter of nuclei (which correlates with ploidy), the phosphorylation of eukaryotic initiation factor 2α (eIF2α, which reflects endoplasmic reticulum stress) as well as the density and ratio of CD8+ cytotoxic T lymphocytes and FOXP3+ regulatory T cells. The median nuclear diameter of malignant cells correlated with eIF2α phosphorylation (in cancerous tissue), which in turn correlated with the density of the CD8+ infiltrate and the CD8+/FOXP3 ratio (both in cancerous and the adjacent non-cancerous parenchyma). Neither microinfiltration nor lymph node involvement was associated with the probability of relapse. Both correlated positively with the CD8+/FOXP3 ratio in the malignant area. In contrast, relapse was associated with a paucity of the CD8+ infiltrate as well as an unfavorable CD8+/FOXP3 ratio, both in malignant and non-malignant parenchyma. The combined analysis of the CD8+/FOXP3 ratio in cancerous and non-cancerous tissues revealed a significant impact of their interaction on the probability of relapse, but not on the presence of microinfiltration or lymph node metastasis. Altogether, these results support the idea of an immunosurveillance system that determines the risk of relapse in ductal carcinoma in situ of the breast.

    langue originaleAnglais
    journalOncoImmunology
    Volume5
    Numéro de publication10
    Les DOIs
    étatPublié - 2 oct. 2016

    Contient cette citation